(2013) Available online at: (accessed March 25, 2019)
For dizziness, try getting up slowly after sitting or lying down to help your body adjust
Finding the Right Doctor Not all doctors have lots of experience with GLP-1 medicines
However, large-scale cardiovascular (CV) outcomes trials (CVOTs) with DPP-4 inhibitors demonstrated CV safety but did not show a reduction in CV events
- The arGLP-1 s have demonstrated a CV benefit in patients with DM2 that appears to extend to patients with reduced renal function
Food and Drug Administration (FDA) accelerated approval for treating metabolic dysfunction-associated steatohepatitis (MASH), the first GLP-1 approved for this indication Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a serious condition that occurs when fat accumulates in the liver, causing inflammation and damage, such as scarring (fibrosis), cirrhosis or liver failure
